切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2026, Vol. 20 ›› Issue (04) : 356 -360. doi: 10.3877/cma.j.issn.1674-3946.2026.04.014

论著

预防性中央区淋巴结清扫在治疗cN0期分化型甲状腺癌的临床分析
王宇男1, 庄大勇2, 周鹏2, 宋泽辉1,()   
  1. 1 161000 黑龙江齐齐哈尔,联勤保障部队第九六一医院普通外科
    2 250031 山东济南,联勤保障部队第九六〇医院甲乳外科
  • 收稿日期:2025-08-27 出版日期:2026-08-26
  • 通信作者: 宋泽辉

Clinical analysis of prophylactic central lymph node dissection in the treatment of cN0 differentiated thyroid carcinoma

Yunan Wang1, Dayong Zhuang2, Peng Zhou2, Zehui Song1,()   

  1. 1 Department of General Surgery, the 96th Hospital of the Joint Logistics Support Force, Qiqihar Heilongjiang Province 161000, China
    2 Department of Breast Surgery, Joint Logistics Support Force 960 Hospital, Jinan Shandong Province 250031, China
  • Received:2025-08-27 Published:2026-08-26
  • Corresponding author: Zehui Song
  • Supported by:
    Shandong Province Medical and Health Science and Technology Development Plan Project(202204011069)
引用本文:

王宇男, 庄大勇, 周鹏, 宋泽辉. 预防性中央区淋巴结清扫在治疗cN0期分化型甲状腺癌的临床分析[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(04): 356-360.

Yunan Wang, Dayong Zhuang, Peng Zhou, Zehui Song. Clinical analysis of prophylactic central lymph node dissection in the treatment of cN0 differentiated thyroid carcinoma[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2026, 20(04): 356-360.

目的

分析预防性中央区淋巴结清扫治疗cN0期分化型甲状腺癌(DTC)的临床效果。

方法

回顾性分析2022年1月至2024年5月行手术治疗的165例cN0期DTC患者资料,根据手术方法分为观察组(n=93,甲状腺腺叶切除联合预防性中央区淋巴结清扫治疗)、对照组(n=72,甲状腺腺叶切除术治疗)。采用SPSS 23.0统计学软件分析数据,围手术期指标、甲状旁腺功能等计量资料以(

±s)表示,组间比较采用t检验;术后并发症发生率、复发率等计数资料以[例(%)]描述,组间比较采用χ2检验;生存分析采用Kaplan-Meier 法检验,使用Log-Rank法分析模型有效性。P<0.05为差异有统计学意义。

结果

观察组手术时间、术中失血量均高于对照组(P<0.05),两组患者住院时间对比差异无统计学意义(P>0.05)。术后7 d,观察组甲状旁腺激素(PTH)、血清钙、CD4+、CD8+低于对照组(P<0.05)。组间并发症总发生率对比差异无统计学意义(P>0.05)。观察组患者术后复发率低于对照组,无进展生存期长于对照组(P<0.05)。

结论

相较于单纯甲状腺腺叶切除术,联合预防性中央区淋巴结清扫治疗cN0期DTC虽会延长手术时间、增加出血量并影响免疫功能,但不会增加并发症发生率,还降低复发率并延长患者无进展生存期。

Objective

To analyze the clinical efficacy of prophylactic central lymph node dissection for clinical node-negative (cN0) differentiated thyroid carcinoma (DTC).

Methods

The clinical data of 165 patients with cN0 DTC who received surgical treatment between January 2022 and May 2024 were retrospectively analyzed. Patients were divided into the observation group (n=93), receiving thyroid lobectomy combined with prophylactic central lymph node dissection) and the control group (n=72), receiving thyroid lobectomy alone). Statistical analysis was performed using SPSS 23.0 software. Measurement data including perioperative indicators and parathyroid gland function parameters were expressed as (mean ± standard) deviation and compared between groups via the t test. Enumeration data such as postoperative complication rates and recurrence rates were presented as [cases (%)], and intergroup comparisons were conducted with the chi-square test. The Kaplan-Meier method was applied for survival analysis, and the Log-Rank test was used to verify the validity of the survival model. A P value less than 0.05 was defined as statistically significant.

Results

The observation group had longer operative duration and greater intraoperative blood loss than the control group (P<0.05). No significant difference in hospital stay was detected between the two groups (P>0.05). On postoperative day 7, the levels of parathyroid hormone (PTH), serum calcium, CD4+ and CD8+ lymphocytes in the observation group were lower than those in the control group (P<0.05). There was no statistically significant intergroup difference in the overall incidence of postoperative complications (P>0.05). The postoperative recurrence rate was lower and progression-free survival was longer in the observation group relative to the control group (P<0.05).

Conclusion

Compared with thyroid lobectomy alone, thyroid lobectomy combined with prophylactic central lymph node dissection for cN0 DTC prolongs operative time, increases intraoperative blood loss and impairs immune function. However, this combined procedure does not raise the incidence of postoperative complications, and can reduce tumor recurrence rate and extend patients' progression-free survival.

表1 cN0期分化型甲状腺癌手术两组患者一般资料比较
表2 cN0期分化型甲状腺癌手术两组患者围手术期指标比较(
±s
表3 cN0期分化型甲状腺癌手术两组患者甲状旁腺功能比较(
±s
表4 cN0期分化型甲状腺癌手术两组患者免疫功能比较(
±s
表5 cN0期分化型甲状腺癌手术两组患者并发症发生情况比较[例(%)]
表6 cN0期分化型甲状腺癌手术两组患者复发率、无进展生存期比较
图1 cN0期分化型甲状腺癌手术两组患者无进展生存期的Kaplan-Meier生存曲线 注:cN0期为临床淋巴结阴性;Log-Rank χ2=6.297,P=0.12;观察组为行甲状腺腺叶切除联合预防性中央区淋巴结清扫;对照组为行甲状腺腺叶切除术
[1]
Bray FLaversanne MSung H,et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin202474(3):229-263.
[2]
袁强,张华宇,闫璋哲,等. cN0峡部偏侧甲状腺乳头状癌中央区淋巴结转移的术前预测模型[J/OL]. 中华普外科手术学杂志(电子版)202519(3):333-336.
[3]
徐金锴,李宗禹,黄新,等. 预防性颈侧区淋巴结清扫对CN0期甲状腺乳头状癌患者甲状腺功能,并发症及预后的影响[J]. 解放军医药杂志202133(10):50-53.
[4]
沈依,李小恩,陈彧泮,等. 甲状腺乳头状癌预防性颈中央区淋巴结清扫对复发率的影响研究[J]. 系统医学20227(22):144-147.
[5]
吴国法,许泽杭,陈施图,等. 甲状腺微小乳头状癌预防性颈中央区淋巴结清扫的研究[J]. 中华普通外科杂志202439(12):953-956.
[6]
Alsubaie KMAlsubaie HMAlzahrani FR,et al. Prophylactic Central Neck Dissection for Clinically Node-Negative Papillary Thyroid Carcinoma[J]. Laryngoscope2022132(6):1320-1328.
[7]
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗202134(12):1164-1201.
[8]
梁龙,苏民富,李嘉根. 甲状腺腺叶切除术两种显露喉返神经方法的临床疗效[J/OL]. 中华普外科手术学杂志(电子版)202115(6):680-682.
[9]
Ringel MDSosa JABaloch Z,et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer[J]. Thyroid202535(08):841-985.
[10]
王旭,刘鹏,王浪. 甲状腺腺叶切除术联合中央区淋巴结清扫治疗分化型甲状腺癌的临床效果[J]. 中国临床医生杂志202452(9):1051-1054.
[11]
宋艾红,陈智杰,陈成,等. 经口腔前庭入路腔镜甲状腺腺叶切除联合中央区淋巴结清扫术的临床应用[J]. 局解手术学杂志202130(9):808-812.
[12]
韩晓刚,孟庆杰,刘向华,等. 预防性中央区淋巴结清扫对cN0甲状腺微小乳头状癌伴桥本甲状腺炎患者免疫功能及预后的影响[J]. 海南医学202233(8):1001-1004.
[13]
李仕发,冉文华,黄自铎. CDC45在甲状腺癌中的表达模式及临床应用价值[J]. 国际免疫学杂志202447(3):229-239.
[14]
石相如,徐晓娅,江剑烨,等. 甲状腺全切联合颈Ⅵ区淋巴结清扫对cN0期甲状腺乳头状癌患者血PTH、Ca2+、CD3+、CD4+、CD8+的影响[J]. 河北医药202042(6):865-867,871.
[15]
纪小宇,张浩. 分化型甲状腺癌中央区淋巴结清扫术范围和指征的发展与思考[J]. 中华外科杂志202563(4):312-317.
[1] 杨明, 许彩娜, 张宁, 王晓娜, 贾坤, 宋伟, 李丽, 薛红元. 2023—2024年度河北省甲状腺癌超声诊断符合率现状分析[J/OL]. 中华医学超声杂志(电子版), 2025, 22(09): 846-849.
[2] 李淳钰, 杨猛. 甲状旁腺全切除术在继发性甲状旁腺功能亢进中的应用现状及展望[J/OL]. 中华普通外科学文献(电子版), 2026, 20(01): 66-72.
[3] 王加中, 曹罡, 刘阳, 陈硕, 李昊煜, 朱绵军, 郑博. 自身免疫性疾病与甲状旁腺功能亢进症的因果关联:孟德尔随机化研究[J/OL]. 中华普通外科学文献(电子版), 2026, 20(01): 35-40.
[4] 孟竹达, 靳亚杰, 郝冉, 赵二鹏. MMIF与围手术期指标预测甲状腺全切术后甲状旁腺功能减退的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(06): 678-681.
[5] 王小贝, 吕庆福, 倪婷. 免充气腋窝入路与全乳晕入路腔镜下甲状腺癌根治术的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(04): 368-371.
[6] 王宇, 徐芳泉, 周旋, 姚晓峰, 李强. 不断提高分化型甲状腺癌根治性切除规范化[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 473-476.
[7] 黄家秀, 古志明, 柯行智, 王超群. 隐匿性甲状腺癌伴肺转移一例[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(02): 338-340.
[8] 李闻天, 李忠慧, 翁云峰, 李儆修, 刘永祥, 徐婧, 贺青卿, 周鹏. 达芬奇机器人辅助儿童甲状旁腺切除术1例[J/OL]. 中华腔镜外科杂志(电子版), 2025, 18(04): 244-246.
[9] 刘凯文, 王焱, 蔡亚囡, 王兆新, 王胜利, 康俊升. 经锁骨下入路腔镜下甲状旁腺切除术[J/OL]. 中华腔镜外科杂志(电子版), 2025, 18(04): 238-240.
[10] 余永武, 熊敏, 张凌. 慢性肾脏病矿物质和骨异常药物治疗研究新进展[J/OL]. 中华肾病研究电子杂志, 2025, 14(01): 44-47.
[11] 郝龙, 张英霞. 原发性甲状旁腺功能亢进热消融的研究进展[J/OL]. 中华临床医师杂志(电子版), 2026, 20(02): 138-144.
[12] 刘皖, 赵婷婷, 魏明辉. 铜绿假单胞菌注射液术区注射治疗颈淋巴结清扫术后顽固性高流量乳糜漏二例及文献复习[J/OL]. 中华临床医师杂志(电子版), 2024, 18(10): 926-930.
[13] 杨菲, 刘腾飞, 赵志军, 李睿聪, 张颉, 刘妍, 赵珍. 血清维生素水平与分化型甲状腺癌的关联性研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 633-640.
[14] 柏兰, 王文斌, 夏泽锋, 刘洋. 肥胖与甲状腺疾病研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2025, 11(02): 129-134.
[15] 张弘玮, 彭刚, 班旭彦, 王晨, 许听, 刘伟杰, 韩晓东. 单孔腹腔镜袖状胃切除术联合经颏下前庭腔镜下甲状腺癌根治术治疗肥胖合并单侧甲状腺癌1 例报道[J/OL]. 中华肥胖与代谢病电子杂志, 2025, 11(01): 76-79.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?